Home » Stocks » PCVX

Vaxcyte, Inc. (PCVX)

Stock Price: $30.00 USD -1.29 (-4.12%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.53B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 50.90M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $30.00
Previous Close $31.29
Change ($) -1.29
Change (%) -4.12%
Day's Open 31.10
Day's Range 28.72 - 31.10
Day's Volume 342,617
52-Week Range 26.15 - 55.40

More Stats

Market Cap 1.53B
Enterprise Value 1.13B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 50.90M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.14M
Short Ratio 11.17
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.01
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 397.05M
Net Cash / Share 7.79
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(65.83% upside)
Current: $30.00
Target: 49.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-54.15-35.53
Net Income-50.27-29.49
Shares Outstanding6.406.14
Earnings Per Share-7.85-4.80
Operating Cash Flow-47.15-30.47
Capital Expenditures-1.20-1.77
Free Cash Flow-48.34-32.24
Cash & Equivalents58.9866.09
Total Debt-0.16
Net Cash / Debt58.9865.93
Book Value-106-57.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vaxcyte, Inc.
Country United States
CEO Grant Pickering

Stock Information

Ticker Symbol PCVX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PCVX
IPO Date June 12, 2020


Vaxcyte, a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.